Compounder refuses to halt production despite FDA alert

By Fiona BARRY

- Last updated on GMT

Qualgen agreed to recall some of its products
Qualgen agreed to recall some of its products

Related tags Fda

The US FDA has issued an alert warning the public not to take drugs marked as sterile by compounding firm Qualgen.

During an inspection of Qualgen’s facility in Edmond, Oklahoma, FDA investigators observed “insanitary conditions, including poor sterile production practices, which raise concerns about Qualgen’s ability to assure the sterility of drug products that it produced,​” said the agency.

The FDA recommended the company cease sterile operations until it fixed the problems, but Qualgen agreed only to voluntarily recall 67 lots of drugs. The recalled products were compounded before September 1, 2015 and have not yet expired.

The Food and Drug Administration said it is not aware of any adverse events associated with Qualgen’s products, but warned:

Health care professionals should immediately check their medical supplies, quarantine any drug products marketed as sterile from Qualgen or Amerilab LLC, the facility’s former name, and not administer them to patients. Administration of a non-sterile drug product intended to be sterile may result in serious and potentially life-threatening infections or death.​”

Compounders: GMP?

Under the November 2013 Drug Quality and Security Act, which added section 503B to the Federal Food, Drug, and Cosmetic Act (FDCA), outsourcing facilities must comply with current good manufacturing practice requirements, are subject to inspection by FDA according to a risk-based schedule; and must report adverse events and provide the FDA with information about the products they compound.

The FDA tightened up rules this year​ on the circumstances under which compounding pharmacies must register as outsourcing facilities.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers